{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:10Z","timestamp":1786985410554,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.blre.2009.09.001","type":"journal-article","created":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T04:17:42Z","timestamp":1255580262000},"page":"39-47","source":"Crossref","is-referenced-by-count":80,"title":["Anemia in renal disease: Diagnosis and management"],"prefix":"10.1016","volume":"24","author":[{"given":"Christina E.","family":"Lankhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2009.09.001_bib1","unstructured":"National Kidney Foundation. Chronic kidney disease. <www.kidney.org\/kidneydisease\/ckd\/index.cfm>; 2009 [accessed 7.07.09]."},{"key":"10.1016\/j.blre.2009.09.001_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1681\/ASN.2004070597","article-title":"Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease","volume":"16","author":"Weiner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib3","unstructured":"World Health Organization. Database of anemia. Worldwide prevalence of anaemia 1993\u20132005. <www.who.int\/vmnis>; 2009 [accessed 7.07.09]."},{"key":"10.1016\/j.blre.2009.09.001_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.V132504","article-title":"Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey","volume":"13","author":"Hsu","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the third national health and nutrition examination survey (1988\u20131994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2009.09.001_bib6","series-title":"Comprehensive clinical nephrology","author":"Fehally","year":"2003"},{"key":"10.1016\/j.blre.2009.09.001_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000187882","article-title":"Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease","volume":"67","author":"Eckardt","year":"1994","journal-title":"Nephron"},{"key":"10.1016\/j.blre.2009.09.001_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archinte.126.5.812","article-title":"Disorders of red cell production in uremia","volume":"126","author":"Eschbach","year":"1970","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2009.09.001_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000180353","article-title":"Anemia of the regular hemodialysis patient and its treatment","volume":"12","author":"Koch","year":"1974","journal-title":"Nephron"},{"key":"10.1016\/j.blre.2009.09.001_bib10","first-page":"585","article-title":"Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA registry","volume":"8","author":"Geerlings","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2009.09.001_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ndt\/14.2.369","article-title":"Fluid state and blood pressure control in patients treated with long and short dialysis","volume":"14","author":"Katzarski","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl. 8","key":"10.1016\/j.blre.2009.09.001_bib12","first-page":"viii29","article-title":"Dialysis adequacy and response to erythropoietic agents: what is the evidence base?","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2009.09.001_bib13","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. <www.kidney.org\/PROFESSIONALS\/kdoqi\/guidelines_anemia\/guide2.htm#cpr11>; 2009 [accessed 7.07.09]."},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/0264-6021:3570241","article-title":"Ferritin and the response to oxidative stress","volume":"357","author":"Orino","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.blre.2009.09.001_bib15","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/ndt\/15.11.1827","article-title":"Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration","volume":"15","author":"Parkkinen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.ackd.2008.12.006","article-title":"Iron and clinical outcomes in dialysis and non-dialysis dependent chronic kidney disease patients","volume":"16","author":"Kovesdy","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1016\/j.blre.2009.09.001_bib17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood-2007-12-126854","article-title":"Iron depletion limits intracellular growth in macrophages","volume":"12","author":"Paradkar","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2009.09.001_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"A potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.blre.2009.09.001_bib19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2215\/CJN.02690409","article-title":"Hepcidin assays: ironing out some details","volume":"4","author":"Malyszko","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib20","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.09.001_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0272-6386(97)90104-9","article-title":"Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO","volume":"30","author":"Mittman","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib22","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1046\/j.1523-1755.2001.00077.x","article-title":"A randomized trial of iron deficiency testing strategies in hemodialysis patients","volume":"60","author":"Fishbane","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2009.09.001_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ajkd.2002.30544","article-title":"Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life","volume":"39","author":"Painter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/ajkd.2001.26824","article-title":"Quality of life in end-stage renal disease patients","volume":"38","author":"Valderrabano","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2004.03.023","article-title":"Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Pisioni","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21307\/immunohematology-2019-736","article-title":"Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure","volume":"12","author":"Popovsky","year":"1996","journal-title":"Immunohematology"},{"key":"10.1016\/j.blre.2009.09.001_bib29","unstructured":"Aranesp (darbepoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc. <www.aranesp.com\/professionalprescribing_information.jsp>; 2007 [accessed 8.07.09]."},{"key":"10.1016\/j.blre.2009.09.001_bib30","unstructured":"Procrit (epoetin alfa) for injecton [prescribing information]. Thousand Oaks, CA: Amgen Inc. Distributed by Ortho Biotech Products, LP: Raritan, NJ. <www.procrit.com\/ppi.pdf>; 2007 [accessed 8.07.09]."},{"key":"10.1016\/j.blre.2009.09.001_bib31","unstructured":"Epogen (epoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc, 2007. <www.epogen.com\/pdf\/epogen_pi.pdf>; 2009 [accessed 8.07.09]."},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/ajkd.2002.33919","article-title":"Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients","volume":"40","author":"Nissenson","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM199808273390902","article-title":"Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of veterans affairs cooperative study group on erythropoietin in hemodialysis patients","volume":"339","author":"Kaufman","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2009.09.001_bib34","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/ndt\/gfh919","article-title":"Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review","volume":"20","author":"Germain","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CNP64113","article-title":"Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study","volume":"64","author":"Provenzano","year":"2005","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.blre.2009.09.001_bib36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/ndt\/gfh021","article-title":"Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients","volume":"19","author":"Jadoul","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.blre.2009.09.001_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CNP63327","article-title":"Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease","volume":"63","author":"Ling","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(06)69120-4","article-title":"Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia","volume":"368","author":"Macdougall","year":"2006","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2009.09.001_bib39","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1093\/ndt\/gfm160","article-title":"Pharmacology of darbepoetin alfa","volume":"22","author":"Macdougall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2009.09.001_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2006-08-019083","article-title":"New agents that stimulate erythropoiesis","volume":"109","author":"Bunn","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1524-4733.2007.00215.x","article-title":"Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV\/AIDS, and chronic kidney disease","volume":"11","author":"Kimel","year":"2008","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.blre.2009.09.001_bib42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2005090997","article-title":"Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients","volume":"17","author":"Regidor","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.blre.2009.09.001_bib43","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2009.09.001_bib44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0272-6386(12)80671-8","article-title":"Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients","volume":"24","author":"Roth","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int"},{"issue":"20","key":"10.1016\/j.blre.2009.09.001_bib46","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1523-1755.2004.00810.x","article-title":"Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients","volume":"66","author":"Frank","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1523-1755.2005.00458.x","article-title":"Spanish group for the study of the anemia and left ventricular hypertrophy in pre-dialysis patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g\/dL","volume":"68","author":"Ayus","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000213166","article-title":"Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis","volume":"32","author":"Wish","year":"2009","journal-title":"Kidney Blood Press Res"},{"issue":"11","key":"10.1016\/j.blre.2009.09.001_bib50","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1345\/aph.1K194","article-title":"Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease","volume":"41","author":"Maddux","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.blre.2009.09.001_bib51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/ajkd.2002.34912","article-title":"Health care resource utilization and the impact of anemia management in patients with chronic kidney disease","volume":"40","author":"London","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.blre.2009.09.001_bib52","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JOM.0b013e318162f615","article-title":"An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease","volume":"50","author":"Papatheofanis","year":"2008","journal-title":"J Occup Environ Med"},{"issue":"1","key":"10.1016\/j.blre.2009.09.001_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/dis.2008.111715","article-title":"The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer\u2019s perspective","volume":"11","author":"Moyneur","year":"2008","journal-title":"Dis Manag"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ndt\/18.2.353","article-title":"A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients","volume":"18","author":"Furuland","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.blre.2009.09.001_bib55","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2004121039","article-title":"Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease","volume":"16","author":"Parfrey","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.blre.2009.09.001_bib56","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.09.001_bib57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Sczcech","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ackd.2008.12.007","article-title":"What is so bad about a hemoglobin of 12\u201313 g\/dL for chronic kidney disease patients anyway?","volume":"16","author":"Besarab","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1291\/hypres.27.79","article-title":"Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients","volume":"27","author":"Miyashita","year":"2004","journal-title":"Hypertens Res"},{"issue":"10","key":"10.1016\/j.blre.2009.09.001_bib60","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib61","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug advents in hemodialysis patients","volume":"37","author":"Fletes","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2009.09.001_bib62","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2009.09.001_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ndt\/17.suppl_5.56","article-title":"Adjunctive therapy in anaemia management","volume":"17","author":"Horl","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.blre.2009.09.001_bib64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1525-139X.2006.00174.x","article-title":"Intravenous iron therapy in end-stage renal disease","volume":"19","author":"Brewster","year":"2006","journal-title":"Semin Dial"},{"issue":"6","key":"10.1016\/j.blre.2009.09.001_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5414\/CNP57457","article-title":"Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients","volume":"57","author":"Hoen","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.blre.2009.09.001_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hep.510250130","article-title":"The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis","volume":"25","author":"Admas","year":"1997","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.blre.2009.09.001_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.ackd.2008.12.009","article-title":"Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation","volume":"16","author":"Adamson","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.blre.2009.09.001_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0027-9684(15)30881-6","article-title":"Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease","volume":"101","author":"Kamgar","year":"2009","journal-title":"J Natl Med Assoc"},{"issue":"9","key":"10.1016\/j.blre.2009.09.001_bib69","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/08860220802353884","article-title":"Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study","volume":"30","author":"Sirover","year":"2008","journal-title":"Renal Failure"},{"issue":"6","key":"10.1016\/j.blre.2009.09.001_bib70","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0272-6386(03)00356-1","article-title":"Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients","volume":"41","author":"Keven","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.blre.2009.09.001_bib71","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1053\/j.ajkd.2005.12.025","article-title":"Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia","volume":"47","author":"Attallah","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2009.09.001_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ndt\/16.suppl_5.35","article-title":"Erythropoietin and iron: the role of ascorbic acid","volume":"16","author":"Tarng","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.blre.2009.09.001_bib73","first-page":"444","article-title":"Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial","volume":"13","author":"Giancaspro","year":"2000","journal-title":"J Nephrol"},{"issue":"Suppl. 69","key":"10.1016\/j.blre.2009.09.001_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69093.x","article-title":"Anemia and carnitine supplementation in hemodialyzed patients","volume":"55","author":"Kletzmayr","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2009.09.001_bib75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0272-6386(95)90439-5","article-title":"l-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin","volume":"26","author":"Labonia","year":"1995","journal-title":"Am J Kidney Dis"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0900054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0900054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T05:45:53Z","timestamp":1634017553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X0900054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0268960X0900054X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2009.09.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}